SCHEMBL4136499

SCHEMBL4136499

COc1c(C(=O)NCC2CC2)ccc2[nH]nc(/C=C/c3ccc(F)cc3)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 15/20 0.41
KMT2A Q03164 1/20 0.40
HTR4 Q13639 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
DYRK1A Q13627 2/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
LYN P07948 1/20 0.38
GRK2 P25098 1/20 0.38
CLK1 P49759 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4136506 1.00 GSK3B (0.41) GSK3BKMT2AHTR4HDAC3HDAC4
SCHEMBL6427314 0.95 HTR4 (0.44) GSK3BKMT2AHTR4HDAC3HDAC4
SCHEMBL4139108 0.92 GSK3B (0.47) GSK3BHTR4DYRK1ACDK2CDK16
SCHEMBL4139103 0.92 GSK3B (0.47) GSK3BHTR4DYRK1ACDK2CDK16
SCHEMBL4135799 0.90 GSK3B (0.42) GSK3BHDAC3HDAC4HDAC1HDAC7
SCHEMBL4135790 0.90 GSK3B (0.42) GSK3BHDAC3HDAC4HDAC1HDAC7
SCHEMBL13927858 0.90 RAB9A (0.39) GSK3BKMT2AHTR4HDAC3HDAC4
SCHEMBL4153490 0.89 HDAC3 (0.44) GSK3BKMT2AHDAC3HDAC4HDAC1
SCHEMBL4153496 0.89 HDAC3 (0.44) GSK3BKMT2AHDAC3HDAC4HDAC1
SCHEMBL4152332 0.89 ALDH2 (0.45) GSK3BKMT2AHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND OHI NORIHITO 2009-02-26 US disclosed
US-7429609-B2 Pyrazole compound and medicinal composition containing the same EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-09-30 US disclosed
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-24 US disclosed
US-20050208582-A1 Pyrazole compounds and pharmaceutical compositions comprising the compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-09-22 US disclosed
EP-1510516-A1 PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME Eisai Co., Ltd. (JP) 2005-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND CNKSR1, NR3C2, CSNK2B GSK3B 418/4885KMT2A 810/4885HTR4 2339/4885
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same CNKSR1, NR3C2, CSNK2B GSK3B 452/4885KMT2A 741/4885HTR4 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.